Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows

Executive Summary

Lower prices for generic drugs in the US are continuing to drag on revenues of drug makers like Teva, Sandoz, Mylan and Endo. Industry leaders say the US market is stabilizing, but price erosion and other negative factors impacted second quarter financials across the sector. Teva is attempting a turnaround and Mylan is exploring strategic alternatives.
Advertisement

Related Content

Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value
Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone
Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Generic Manufacturers Try To Up Their Game As US Pressure Persists
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel